estimate. These tables and charts are available as Adobe Acrobat files.

• Thematic Maps—Display geographic variation in map format from the geographic ranking tables.

• Geographic Comparison Tables—These are single-variable tables comparing key indicators for geographies other than States.

• Subject Tables—These tables highlight a particular subject of interest.

• Selected Population Profiles—Data profiles for selected population groups.

• Public Use Microdata Sample File (PUMS)—Computerized files containing record-level data that can be used to create custom analyses. The geography on these files is the same as the PUMS that were defined for the Census 2000 Sample PUMS files.

Please go to the American FactFinder (AFF) Web site to review each data product in detail. Users can access the AFF from the Census Bureau's home page at *http://www.census.gov/.*, or from the AFF link on the ACS home page at *http://www.census.gov/acs/www/*. Users can view and download each data product. If you have questions about any of these data products, please contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section of this notice.

Paperwork Reduction Act

Notwithstanding any other provision of law, no person is required to respond to, nor shall a person be subject to a penalty for failure to comply with, a collection of information subject to requirements of the Paperwork Reduction Act (PRA), unless that collection of information displays a current, valid Office of Management and Budget (OMB) control number. In accordance with the PRA, 44 United States Code, Chapter 35, the OMB approved the ACS survey under OMB Control Number 0607–0810. We will furnish report forms to organizations included in the survey, and additional copies will be available upon written request to the Director, U.S. Census Bureau, Washington, DC 20233–0101.

Dated: August 21, 2007.

Charles Louis Kincannon,

Director, Bureau of the Census.

[FR Doc. E7–16850 Filed 8–27–07; 8:45 am]

BILLING CODE 3510–07–P

DEPARTMENT OF COMMERCE

Bureau of Economic Analysis

Proposed Information Collection; Comment Request; Expenditures Incurred by Recipients of Bio-Medical Research and Development Awards From the National Institutes of Health (NIH)

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)).

DATES: Written comments must be submitted on or before 5 p.m. October 29, 2007.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230, or via e-mail at *dhynek@doc.gov.*

FOR FURTHER INFORMATION CONTACT: Charlotte Anne Bond, Government Fixed Assets Branch, Government Division (BE–57), Bureau of Economic Analysis, U.S. Department of Commerce, Washington, DC 20230; phone: (202) 606–5581; fax: (202) 606–5369; or via e-mail at *CharlotteAnne.Bond@bea.gov.*

SUPPLEMENTARY INFORMATION:

I. Abstract

The Bureau of Economic Analysis (BEA) will administer a survey to obtain the distribution of expenditures incurred by recipients of bio-medical research awards from the National Institutes of Health Research (NIH) and will provide information on how the NIH award amounts are expended across several major categories. This information, along with wage and price data from other published sources, will be used to generate the Bio-medical Research and Developmental Price Index (BRDPI). BEA develops this index for NIH under a reimbursable contract. The BRDPI is an index of prices paid for the labor, supplies, equipment, and other inputs required to perform the bio-medical research the NIH supports in its intramural laboratories and through its awards to extramural organizations. The BRDPI is a vital tool for planning the NIH research budget and analyzing future NIH programs. A survey of award recipient entities is currently the only means for updating the expenditure categories that are used to prepare the BRDPI.

II. Authority

This survey will be voluntary. The authority for NIH to collect information for the BRDPI is provided in 45 CFR subpart C, Post-Award Requirements, section 74.21. This sets forth explicit standards for grantees in establishing and maintaining financial management systems and records, and section 74.53 which provides for the retention of such records as well as NIH access to such records.

BEA will administer the survey and analyze the survey results on behalf of NIH, through an interagency agreement between the two agencies. The authority for the NIH to contract with DOC is the Economy Act (31 U.S.C. 1535 and 1536).

The ''Special Studies'' authority, 15 U.S.C. 1525 (first paragraph), permits DOC to provide, upon the request of any person, firm or public or private organization (a) Special studies on matters within the authority of the Department of Commerce, including preparing from its records special compilations, lists, bulletins, or reports, and (b) furnishing transcripts or copies of its studies, compilations and other records. BEA has programmatic authority to perform this work pursuant to 15 U.S.C. 1527a. NIH's support for this research is consistent with the Agency's duties and authority under 42 U.S.C. 282.

The information provided by the respondents will be held confidential and be used for exclusively statistical purposes. This pledge of confidentiality is made under the Confidential Information Protection provisions of title V, subtitle A, Public Law 107–347. Title V is the Confidential Information Protection and Statistical Efficiency Act of 2002 (CIPSEA). Section 512 (on Limitations on Use and Disclosure of Data and Information) of the Act, provides that ''data or information acquired by an agency under a pledge of confidentiality and for exclusively statistical purposes shall be used by officers, employees, or agents of the agency exclusively for statistical purposes. Data or information acquired by an agency under a pledge of confidentiality for exclusively statistical purposes shall not be disclosed by an agency in identifiable form, for any use other than an exclusively statistical purpose, except with the informed consent of the respondent.''

Responses will be kept confidential and will not be disclosed in identifiable form to anyone other than employees or

agents of BEA without prior written permission of the person filing the report. By law, each employee as well as each agent is subject to a jail term of up to 5 years, a fine of up to $250,000, or both for disclosing to the public any identifiable information that is reported about a business or institution.

Section 515 of the Information Quality Guidelines applies to this survey. The collection and use of this information complies with all applicable information quality guidelines, i.e., those of the Office of Management and Budget, Department of Commerce, and BEA.

III. Method of Collection

A survey with a cover letter that includes a brief description of, and rationale for, the survey will be sent by e-mail to potential respondents by the first week of June of each year. A report of the respondent's expenditures of the NIH award amounts, following the proposed format for expenditure categories included with the survey's cover letter, will be requested to be completed and submitted online no later than 60 days after mailing. Survey respondents will be selected on the basis of award levels, which determine the weight of the respondent in the biomedical research and development price index. Potential respondents will include (1) the top 100 organizations in total awards, which account for about 74 percent of total awards; (2) 40 additional organizations that are not primarily in the ''Research and Development (R&D) contracts'' category; and (3) 10 additional organizations that are primarily in the ''R&D contracts'' category.

IV. Data

OMB Number: 0608–0069.
Form Number: None.
Type of Review: Regular submission.
Affected Public: Universities or other organizations that are NIH award recipients.
Estimated Number of Respondents: 90.
Estimated Time per Response: 11 hours and 12 minutes.
Estimated Total Annual Burden Hours: 1,008.
Estimated Total Annual Cost: $41,610.

V. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the NIH, including whether the information has practical utility: (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; They also will become a matter of public record.

Dated: August 22, 2007.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E7–16965 Filed 8–27–07; 8:45 am]

BILLING CODE 3510–EA–P

DEPARTMENT OF COMMERCE

Foreign–Trade Zones Board

[Docket 38–2007]

Foreign–Trade Zone 7—Mayaguez, Puerto Rico, Application for Subzone, MOVA Pharmaceutical Corporation (Pharmaceutical Manufacturing), Manatí, Puerto Rico

An application has been submitted to the Foreign–Trade Zones (FTZ) Board (the Board) by the Puerto Rico Industrial Development Company, grantee of FTZ 7, requesting special–purpose subzone status with manufacturing authority for pharmaceutical products at the pharmaceutical manufacturing facility of MOVA Pharmaceutical Corporation (MOVA), located in Manat´, Puerto Rico. The application was submitted pursuant to the Foreign–Trade Zones Act, as amended (19 U.S.C. 81a–81u), and the regulations of the Board (15 CFR part 400). It was formally filed on August 14, 2007.

The proposed subzone facility (104 acres, 17 buildings totaling 410, 000 sq. ft., 40 percent of which is devoted to manufacturing) is located at State Road 670, Km 2.7 in Manat´, Puerto Rico. The company has indicated that the square footage of the buildings devoted to manufacturing operations could increase to include up to 70 percent of the total in the near future.

The MOVA facility (310 employees) has requested authority to manufacture two pharmaceutical products, Januvia/MK–431A (HTSUS 3004.90) and sitagliptin (HTSUS 2933.59), on behalf of Merck, Sharpe & Dohme Quimica de Puerto Rico, Inc. Duty rates on the finished products range from duty–free to 6.5 percent, *ad valorem*. Foreign–origin material inputs to be used in the manufacturing process (up to 25 percent of total materials, by value) include sitagliptin (HTSUS 2933.59), metformin hydrochloride (HTSUS 2925.20), enamine amide (HTSUS 2933.59), and butyl josphos (HTSUS 2931.00), which have duty rates of 3.7 percent to 6.5 percent, *ad valorem*.

The application also requests authority to include a broad range of inputs and finished pharmaceutical products that MOVA may produce under FTZ procedures in the future. (As required by the Board's regulations, new major activity involving these inputs/products would require review by the Board.) The duty rates for these inputs and final products range from duty–free to 10 percent.

FTZ procedures would exempt MOVA from customs duty payments on foreign materials used in export production to non–NAFTA countries. Some 30 to 40 percent of the plant's shipments are exported. On its domestic shipments and sales to NAFTA countries, MOVA could defer duty until the products are entered for consumption or exported, and choose the lower duty rate that applies to the finished product for the foreign components used in production. The company may also realize certain logistical/procedural savings related to zone–to zone transfers and direct delivery procedures as well as savings on materials that become scrap/waste during manufacturing. The application indicates that FTZ procedures would help improve the plant's international competitiveness.

In accordance with the Board's regulations, a member of the FTZ staff has been designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board's Executive Secretary at the address below. The closing period for their receipt is October 29, 2007. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period (to November 13, 2007).

A copy of the application will be available for public inspection at each of the following locations: U.S. Department of Commerce Export Assistance Center, Centro Internacional de Mercado, Tower II, Suite 702, Road 165, Guaynabo, Puerto Rico, 00968–8058; and, Office of the Executive Secretary, Foreign–Trade Zones Board, Room 2111, U.S. Department of